Exodus Point Capital Management, LP Corvus Pharmaceuticals, Inc. Call Options Transaction History
Exodus Point Capital Management, LP
- $14.6 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRVS
# of Institutions
96Shares Held
39.9MCall Options Held
1.95MPut Options Held
462K-
Orbimed Advisors LLC San Diego, CA6.94MShares$33.9 Million0.98% of portfolio
-
Samlyn Capital, LLC New York, NY6.67MShares$32.5 Million0.56% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$16 Million18.22% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.03MShares$14.8 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$13.1 Million0.23% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $227M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...